Profile: Santarus, Inc. (SNTS.O)

Santarus, Inc. (Santarus), incorporated in December 1996, is a specialty pharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by gastroenterologists or primary care physicians. Santarus focuses on commercializing of its Zegerid immediate-release proton pump inhibitor (PPI) products. PPI products are used for the treatment of many upper gastrointestinal (GI) diseases and disorders, including gastroesophageal reflux disease (GERD). The Company’s Zegerid products are immediate-release formulations that combine omeprazole, a PPI, and one or more antacids.

Zegerid Capsules and Zegerid Powder for Oral Suspension

Santarus’ Zegerid Capsules product is an immediate-release formulation that contains omeprazole and sodium bicarbonate in a capsule dosage form and is available in 20 milligram/1100 milligram and 40 milligram/1100 milligram dosage strengths. The Company’s Zegerid Powder for Oral Suspension product is an immediate-release formulation that contains omeprazole and sodium bicarbonate in a powder for oral suspension dosage form and is available in 20 milligram/1680 milligram and 40 milligram /1680 milligram dosage strengths. Zegerid Capsules are indicated for the treatment of heartburn and other symptoms associated with GERD, short-term treatment (4 to 8 weeks) of erosive esophagitis, which has been diagnosed by endoscopy, maintenance of healing of erosive esophagitis, short-term treatment of active duodenal ulcers, and short-term treatment (4 to 8 weeks) of active benign gastric ulcers. Zegerid products utilize one or more antacids, instead of an enteric coating to protect the omeprazole from acid degradation.

Glumetza Extended Release Tablets

Glumetza (metformin hydrochloride extended release tablets) is a once-daily, extended-release formulation of metformin in 500 mg and 1000 mg dosage strengths. These tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

The Company's competitors include Novartis AG and Takeda Pharmaceutical Company Limited.